Hormonal remodeling and molecular mechanisms in postmenopausal osteoporosis: Pathogenesis and therapeutic implications (Review)

Postmenopausal osteoporosis (PMO) is a prevalent metabolic bone disorder characterized by accelerated bone loss, reduced bone mineral density, and increased fragility fracture risk.Although estrogen deficiency is considered a central driver of PMO, increasing evidence indicates that bone loss after menopause results from broader endocrine remodeling involving multiple hormones.Estrogen decline and the accompanying rise in follicle-stimulating hormone (FSH) are characteristic of the menopausal transition.Alterations in the parathyroid hormone (PTH)-vitamin d axis, oxytocin (OT) and calcitonin (CT) may also influence skeletal homeostasis, although their patterns and causal contributions are less consistently established in postmenopausal women.These pathways are discussed as interacting components of an endocrine framework with differing levels of supporting evidence.These coordinated hormonal alterations disrupt bone remodeling through several mechanisms, including impaired bone mechanical homeostasis, dysregulated osteoimmune interactions, altered calcium metabolism, and gut microbiota-bone axis imbalance.collectively, these changes promote osteoclast activation, suppress osteoblast function, and accelerate skeletal deterioration.current therapeutic approaches, such as hormone replacement therapy, bisphosphonates, selective estrogen receptor modulators, and PTH analogs, have improved the management of PMO but remain limited by safety concerns or restricted long-term efficacy.Emerging approaches, including FSH blockade, selected phytoestrogen-related interventions, modified CT delivery, and OT-related pathways have different levels of supporting evidence; most specific experimental strategies require human efficacy and safety validation before clinical application.An improved understanding of hormonal interactions and endocrine network remodeling may facilitate the development of more precise and individualized strategies for the prevention and treatment of PMO.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Medicine
Published
2026-10-26
DOI
https://doi.org/10.3892/ijmm.2026.6027
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hormonal remodeling and molecular mechanisms in postmenopausal osteoporosis: Pathogenesis and therapeutic implications (Review)

Liu Yang, Wenjun Liu, Haimin Zeng, Chenyu Zhang et al.
International Journal of Molecular Medicine
Bone health and osteoporosis research
article

Hormonal remodeling and molecular mechanisms in postmenopausal osteoporosis: Pathogenesis and therapeutic implications (Review)

Liu Yang, Wenjun Liu, Haimin Zeng, Chenyu Zhang, Ruhui Yang, Yining Xie, Penglin Wang, Jiahao Zeng, Zhengzheng Li, Sijian Lin
article en

Abstract

Postmenopausal osteoporosis (PMO) is a prevalent metabolic bone disorder characterized by accelerated bone loss, reduced bone mineral density, and increased fragility fracture risk.Although estrogen deficiency is considered a central driver of PMO, increasing evidence indicates that bone loss after menopause results from broader endocrine remodeling involving multiple hormones.Estrogen decline and the accompanying rise in follicle-stimulating hormone (FSH) are characteristic of the menopausal transition.Alterations in the parathyroid hormone (PTH)-vitamin d axis, oxytocin (OT) and calcitonin (CT) may also influence skeletal homeostasis, although their patterns and causal contributions are less consistently established in postmenopausal women.These pathways are discussed as interacting components of an endocrine framework with differing levels of supporting evidence.These coordinated hormonal alterations disrupt bone remodeling through several mechanisms, including impaired bone mechanical homeostasis, dysregulated osteoimmune interactions, altered calcium metabolism, and gut microbiota-bone axis imbalance.collectively, these changes promote osteoclast activation, suppress osteoblast function, and accelerate skeletal deterioration.current therapeutic approaches, such as hormone replacement therapy, bisphosphonates, selective estrogen receptor modulators, and PTH analogs, have improved the management of PMO but remain limited by safety concerns or restricted long-term efficacy.Emerging approaches, including FSH blockade, selected phytoestrogen-related interventions, modified CT delivery, and OT-related pathways have different levels of supporting evidence; most specific experimental strategies require human efficacy and safety validation before clinical application.An improved understanding of hormonal interactions and endocrine network remodeling may facilitate the development of more precise and individualized strategies for the prevention and treatment of PMO.

International Journal of Molecular MedicineVol. 58(6)
Nanchang University (CN), Second Affiliated Hospital of Nanchang University (CN)
Jiangxi Provincial Department of Science and Technology, Health Commission of Jiangxi Province
Openalex Percentile: Top 10%
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon